279 related articles for article (PubMed ID: 26655062)
1. Controlled release of biologics for the treatment of type 2 diabetes.
Gilroy CA; Luginbuhl KM; Chilkoti A
J Control Release; 2016 Oct; 240():151-164. PubMed ID: 26655062
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
3. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
[TBL] [Abstract][Full Text] [Related]
4. Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review.
Jendle J; Martin SA; Milicevic Z
Expert Opin Investig Drugs; 2012 Oct; 21(10):1463-74. PubMed ID: 22799463
[TBL] [Abstract][Full Text] [Related]
5. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
6. Peptide drug delivery strategies for the treatment of diabetes.
Sadrzadeh N; Glembourtt MJ; Stevenson CL
J Pharm Sci; 2007 Aug; 96(8):1925-54. PubMed ID: 17286287
[TBL] [Abstract][Full Text] [Related]
7. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
[TBL] [Abstract][Full Text] [Related]
8. New concepts in diabetes: how multihormonal regulation can improve glycemic control.
Blonde L; Baker DE; Davis SN; Ratner RE
J Manag Care Pharm; 2004 Dec; 10(6 Suppl B):S3-8; quiz S9, S11-2. PubMed ID: 23570175
[TBL] [Abstract][Full Text] [Related]
9. Dual self-regulated delivery of insulin and glucagon by a hybrid patch.
Wang Z; Wang J; Li H; Yu J; Chen G; Kahkoska AR; Wu V; Zeng Y; Wen D; Miedema JR; Buse JB; Gu Z
Proc Natl Acad Sci U S A; 2020 Nov; 117(47):29512-29517. PubMed ID: 33177238
[TBL] [Abstract][Full Text] [Related]
10. Oral insulin delivery: existing barriers and current counter-strategies.
Gedawy A; Martinez J; Al-Salami H; Dass CR
J Pharm Pharmacol; 2018 Feb; 70(2):197-213. PubMed ID: 29193053
[TBL] [Abstract][Full Text] [Related]
11. Buccal spray insulin (Oralgen) for type 2 diabetes: what evidence?
Palermo A; Maddaloni E; Pozzilli P
Expert Opin Biol Ther; 2012 Jun; 12(6):767-72. PubMed ID: 22515262
[TBL] [Abstract][Full Text] [Related]
12. Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus.
Freeman JS
J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S2-6. PubMed ID: 22267300
[TBL] [Abstract][Full Text] [Related]
13. Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial.
Polderman JA; Houweling PL; Hollmann MW; DeVries JH; Preckel B; Hermanides J
BMC Anesthesiol; 2014; 14():91. PubMed ID: 25419179
[TBL] [Abstract][Full Text] [Related]
14. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
Egan JM; Meneilly GS; Habener JF; Elahi D
J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
[TBL] [Abstract][Full Text] [Related]
16. Novel strategies in the oral delivery of antidiabetic peptide drugs - Insulin, GLP 1 and its analogs.
Ismail R; Csóka I
Eur J Pharm Biopharm; 2017 Jun; 115():257-267. PubMed ID: 28336368
[TBL] [Abstract][Full Text] [Related]
17. BPI-3016, a novel long-acting hGLP-1 analogue for the treatment of Type 2 diabetes mellitus.
Ding L; Lu S; Wang Y; Chen H; Long W; Ma C; He E; Yan D; Tan F
Pharmacol Res; 2017 Aug; 122():130-139. PubMed ID: 28619366
[TBL] [Abstract][Full Text] [Related]
18. New Insulins and New Aspects in Insulin Delivery.
Woo VC
Can J Diabetes; 2015 Aug; 39(4):335-43. PubMed ID: 26233724
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes.
Marino MT; Costello D; Baughman R; Boss A; Cassidy J; Damico C; van Marle S; van Vliet A; Richardson PC
Clin Pharmacol Ther; 2010 Aug; 88(2):243-50. PubMed ID: 20592721
[TBL] [Abstract][Full Text] [Related]
20. The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin.
Shaefer CF; Anderson J
Postgrad Med; 2016 Jan; 128(1):137-44. PubMed ID: 26548422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
